Alzheimer's disease drug development pipeline: 2019

By Jeffrey L. Cummings, Garam Lee, A. Ritter, M. Sabbagh, K. Zhong. Alzheimer's & Dementia, 2019

682 citations recorded by the source corpus.

Alzheimer's disease (AD) has few available treatments, and there is a high rate of failure in AD drug development programs. Study of the AD drug development pipeline can provide insight into the evolution of drug development and how best to optimize development practices.

Subfields: Pharmacology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/39947d9225c17b3903f9c0803f67018762b8c6ab